• Prostate Cancer
    • Peter T Scardino
    • Peter T Scardino: Influence Statistics

      Peter T Scardino

      Peter T Scardino

      Show email address

      Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Peter T Scardino:Expert Impact

      Concepts for whichPeter T Scardinohas direct influence:Prostate cancer,Radical prostatectomy,Active surveillance,Erectile function,Biochemical recurrence,Specific antigen,Localized prostate cancer,Positive surgical margins.

      Peter T Scardino:KOL impact

      Concepts related to the work of other authors for whichfor which Peter T Scardino has influence:Prostate cancer,Active surveillance,Specific antigen,Biochemical recurrence,Gleason score,Prostatic neoplasms,Androgen receptor.

      KOL Resume for Peter T Scardino


      Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

      Memorial Sloan Kettering Cancer Center, New York, NY;


      Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.


      Department of Surgery.


      Department of Urology, Memorial Sloan‐Kettering Cancer Center, New York, NY, USA

      New York, NY;


      Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, USA

      Weill Cornell Medical College, New York, New York


      Debra A Goldman, Department of Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, United States

      Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

      Memorial Sloan Kettering Cancer CenterNew York, NY.


      Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

      Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY


      Urology Service, Department of Surgery and Department of Epidemiology and Biostatistics (MJA, DDS, AJV), Memorial Sloan Kettering Cancer Center, New York, New York


      Department of Surgery, The Urology Service, Sidney Kimmel Center for Prostate and Urological Malignancies and Memorial Sloan-Kettering Cancer Center, New York, NY, USA

      Urology, and


      Authors' Affiliations: 1Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center; Departments of 2Surgery, 3Medicine, 4Pathology, 5Biostatistics, and 6Immunology, Memorial Sloan-Kettering Cancer Center; 7NYU Langone Medical Center, New York; 8Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama; 9RIKEN Bioresource Center, Tsukuba, Ibaraki, Japan; and 10Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt, Germany

      Urology Service Department of Surgery New York NY USA

      Transatlantic Prostate Group

      Memorial Sloan-Kettering Cancer Center, New York, New York

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Peter T Scardino is among the top experts in the world.
      Concept World rank
      rp urinary continence #1
      btb 24 months #1
      subjective characterization #1
      prediction insignificant disease #1
      sebrt patients #1
      obturator hypogastric area #1
      catheter removal rp #1
      psm p0002 #1
      klk2 hk2 #1
      hk2 unfavorable prognosis #1
      t2b lobe #1
      symptomatic lymphocele rp #1
      nerve graft placement #1
      svi conventional criteria #1
      irradiated prostate cancers #1
      small prostate cancers #1
      prert postrt mri #1
      1992 t2a t2b #1
      baseline total psa #1
      lnm radical prostatectomy #1
      recovery potency #1
      distal apex #1
      apical psm aa #1
      psm sebrt #1
      metastasis freedom #1
      baseline prostate cancer #1
      recovery radical #1
      current diagnostic tests #1
      individual patients percentage #1
      recovery continence #1
      trial radical prostatectomy #1
      recovery 2 years #1
      stage tumors cent #1
      biopsy humans tests #1
      confirmatory biopsy rp #1
      development bcr #1
      delay bcr #1
      göteborg rotterdam #1
      tests prostatic neoplasms #1
      sebrt local neoplasm #1
      lesion spga #1
      t2c tumors differences #1
      radical prostatectomy progression #1
      extension seminal #1
      level extent #1
      progression tumor biopsy #1
      case‐mix‐adjusted #1
      endorectal imaging svi #1
      p00001 nsms #1
      intensitypercentage #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Peter T Scardino

      KOL-Index: 18544

      CONTEXT: The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use.

      OBJECTIVE: To develop risk assessment guidelines and a cutoff value for defining abnormal percentage of free PSA in a population of men to whom the test would be applied.

      DESIGN: Prospective blinded study using the Tandem PSA and free PSA assays (Hybritech ...

      Known for Prostate Cancer | Percentage Free Psa | Benign Prostatic Disease | Specific Antigen | Unnecessary Biopsies
      KOL-Index: 17052

      To determine the characteristics of transition zone and peripheral zone prostate cancer, we examined a series of 42 stage A and 54 stage B radical prostatectomy specimens with particular attention to the number of separate foci of cancer, zone of origin, volume and grade of each focus, and presence of severe intraductal dysplasia (high grade prostatic intraepithelial neoplasia), extra-capsular extension and seminal vesicle invasion associated with cancer in each zone. We found that there ...

      Known for Peripheral Zone | Morphological Features | Volume Grade | Extracapsular Extension | Stage Cancer
      KOL-Index: 17012

      CONTEXT: Salvage radiotherapy may potentially cure patients with disease recurrence after radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at the highest risk of metastatic disease progression.

      OBJECTIVE: To delineate patients who may benefit from salvage radiotherapy for prostate cancer recurrence by identifying variables associated with a durable response.

      DESIGN, SETTING, AND PATIENTS: Retrospective review of a cohort of 501 patients at 5 ...

      Known for Salvage Radiotherapy | Radical Prostatectomy | 95 Patients | Prostate Cancer | Durable Response
      KOL-Index: 16699

      PURPOSE: We evaluated predictors of progression after starting active surveillance, especially the role of prostate specific antigen and immediate confirmatory prostate biopsy.

      MATERIALS AND METHODS: A total of 238 men with prostate cancer met active surveillance eligibility criteria and were analyzed for progression with time. Cox proportional hazards regression was used to evaluate predictors of progression. Progression was evaluated using 2 definitions, including no longer meeting 1) ...

      Known for Specific Antigen | Confirmatory Biopsy | Active Surveillance | Risk Prostate | Predictors Progression
      KOL-Index: 16639

      PURPOSE: Cancer at the resection margin (a positive surgical margin) after radical prostatectomy is associated with an increased risk of recurrence even after adjusting for other known risk factors, including pretreatment serum prostate specific antigen (PSA), clinical stage, grade and pathological stage (level of extracapsular extension, seminal vesicle invasion and pelvic lymph node status). Of these prognostic factors only surgical margin status can be influenced by surgical ...

      Known for Positive Surgical Margins | Radical Prostatectomy | Extracapsular Extension | Surgeon Volume | Gleason Sum
      KOL-Index: 16128

      To compare the efficacy of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer, we conducted a prospective clinical trial at 6 university centers of 6,630 male volunteers 50 years old or older who underwent PSA determination (Hybritech Tandem-E or Tandem-R assays) and digital rectal examination. Quadrant biopsies were performed if the PSA level was greater than 4 micrograms/l or digital rectal examination was suspicious, even if ...

      Known for Digital Rectal Examination | Prostate Cancer | Early Detection | Specific Antigen | Biopsy Humans
      KOL-Index: 16113

      OBJECTIVES: Various methods have been proposed to increase the specificity of prostate-specific antigen (PSA), including age-specific PSA reference ranges, PSA density (PSAD), and percent free PSA (%fPSA). In this multicenter study, we compared these methods for their utility in cancer detection and their ability to predict pathologic stage after radical prostatectomy in patients with clinically localized, Stage T1c cancer.

      METHODS: Seven hundred seventy-three men (379 with prostate ...

      Known for Cancer Detection | Psa Density | Percent Free | Age Specific | Radical Prostatectomy
      KOL-Index: 16038

      OBJECTIVE: To determine the relation between concentrations of prostate specific antigen at age 60 and subsequent diagnosis of clinically relevant prostate cancer in an unscreened population to evaluate whether screening for prostate cancer and chemoprevention could be stratified by risk.

      DESIGN: Case-control study with 1:3 matching nested within a highly representative population based cohort study.

      SETTING: General population of Sweden taking part in the Malmo Preventive Project. ...

      Known for Prostate Cancer | Specific Antigen | Age 60 | Metastasis Death | Casecontrol Study
      KOL-Index: 15815

      Objective. —To combine the clinical data from 3 academic institutions that serve as centers of excellence for the surgical treatment of clinically localized prostate cancer and develop a multi-institutional model combining serum prostate-specific antigen (PSA) level, clinical stage, and Gleason score to predict pathological stage for men with clinically localized prostate cancer.Design. —In this update, we have combined clinical and pathological data for a group of 4133 men treated by ...

      Known for Pathological Stage | Gleason Score | Localized Prostate Cancer | Seminal Vesicle Involvement | Nomograms Probability
      KOL-Index: 15727

      BACKGROUND: In carcinoma of the bladder, both intravesical chemotherapy and immunotherapy can induce tumor regression and reduce the rate of recurrence, but the relative merits of these two therapies are unclear. We conducted a multi-institutional study to address this question.

      METHODS: Patients with rapidly recurrent (stage Ta and T1) or in situ transitional-cell carcinoma of the bladder were randomly assigned to receive either doxorubicin administered intravesically or bacille ...

      Known for Patients Carcinoma | Intravesical Doxorubicin | Immunotherapy Bcg | Neoplasm Recurrence | Treatment Failure
      KOL-Index: 15665

      PURPOSE: The accurate prediction of pathological stage of prostate cancer using preoperative factors is a critical aspect of treatment. In 1997 Partin et al published tables predicting pathological stage using clinical stage, Gleason score and prostate specific antigen (PSA). We tested the validity of the Partin tables.

      MATERIALS AND METHODS: From 1990 to 1996 inclusively 5,780 patients underwent bilateral pelvic lymphadenectomy and radical prostatectomy for prostate cancer at the Mayo ...

      Known for Pathological Stage | Partin Tables | Prostate Cancer | Neoplasms Roc | Gleason Score
      KOL-Index: 15536

      PURPOSE: To our knowledge the ideal methodology of quantifying secondary Gleason pattern 4 in men with Grade Group 2/Gleason score 3 + 4 = 7 on biopsy remains unknown. We compared various methods of Gleason pattern 4 quantification and evaluated associations with adverse pathology findings at radical prostatectomy.

      MATERIALS AND METHODS: A total of 457 men with Grade Group 2 prostate cancer on biopsy subsequently underwent radical prostatectomy at our institution. Only patients with 12 ...

      Known for Gleason Pattern | Total Length | Prostate Cancer | Adverse Pathology | Grade 2
      KOL-Index: 15462

      This study was designed to determine the effects of age by decade on the efficacy of digital rectal examination (DRE) and serum prostate-specific antigen (PSA) for early detection of prostate cancer in men aged fifty and over. A prospective multicenter clinical trial was conducted at six university centers. All 6,630 male volunteers underwent a serum PSA (Hybritech, Tandem) determination and DRE. Quadrant biopsies of the prostate were performed if PSA was > 4 ng/mL or DRE suspicious. A ...

      Known for Early Detection | Prostate Cancer | Digital Rectal Examination | Specific Antigen | Patient Age
      KOL-Index: 15342

      PURPOSE: Although models exist that place patients into discrete groups at various risks for disease recurrence after surgery for prostate cancer, we know of no published work that combines pathologic factors to predict an individual's probability of disease recurrence. Because clinical stage and biopsy Gleason grade only approximate pathologic stage and Gleason grade in the prostatectomy specimen, prediction of prognosis should be more accurate when postoperative information is added to ...

      Known for Disease Recurrence | Postoperative Nomogram | Radical Prostatectomy | Prostate Cancer | Gleason Grade

      Key People For Prostate Cancer

      Top KOLs in the world
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Peter T Scardino
      prostate cancer active surveillance erectile function
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      Johnathan I Jonathan
      prostate cancer gleason score needle biopsy
      Philip W Kantoff
      prostate cancer psma adc androgen deprivation therapy
      prostate cancer specific antigen pathological stage

      Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. | Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York | Memorial Sloan Kettering Cancer Center, New York, NY; | Urology S

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.